Breaking News Instant updates and real-time market news.

CMCSA

Comcast

$39.58

0.08 (0.20%)

, SKYAY

Sky

$61.60

-0.18 (-0.29%)

09:14
02/27/18
02/27
09:14
02/27/18
09:14

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Macy's (M), up 8.5%... Tenet (THC), up 9.5%... Palo Alto Networks (PANW), up 6%... Mallinckrodt (MNK), up 13%. DOWN AFTER EARNINGS: Nutrisystem (NTRI), down 27%... Veritone (VERI), down 13.5%... Fitbit (FIT), down 13%... Exelixis (EXEL), down 2.5%. ALSO LOWER: Comcast (CMCSA), down 4% after the company announced a possible offer which it says is a "superior cash proposal" to acquire Sky (SKYAY). Comcast's superior cash proposal implies an equity value of $31B for Sky... Akorn (AKRX), down 32% after Fresenius (FSNUY) said it is conducting an investigation into alleged Akorn FDA data breaches.

CMCSA

Comcast

$39.58

0.08 (0.20%)

SKYAY

Sky

$61.60

-0.18 (-0.29%)

M

Macy's

$27.45

(0.00%)

MNK

Mallinckrodt

$16.19

(0.00%)

THC

Tenet

$19.07

(0.00%)

PANW

Palo Alto Networks

$169.32

(0.00%)

AKRX

Akorn

$30.28

0.16 (0.53%)

FSNUY

Fresenius SE

$20.14

0.475 (2.42%)

NTRI

Nutrisystem

$39.90

-1.65 (-3.97%)

VERI

Veritone

$18.09

2.71 (17.62%)

FIT

Fitbit

$5.54

(0.00%)

EXEL

Exelixis

$29.53

0.02 (0.07%)

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 05

    Mar

  • 05

    Mar

  • 08

    Mar

  • 11

    Mar

  • 14

    Mar

  • 18

    Mar

  • 19

    Apr

CMCSA Comcast
$39.58

0.08 (0.20%)

01/28/18
PIPR
01/28/18
NO CHANGE
PIPR
Growth of sports rights may be coming down, says Piper Jaffray
Piper Jaffray analyst Stan Meyers says he is starting to see some evidence that the growth of sports rights may be coming down toward a more reasonable rate. The analyst notes that only CBS (CBS), Fox (FOXA) and NBC (CMCSK; CMCSA) submitted bids for Thursday Night Football rights, with CBS and NBC submitting bids below their current rate of $450M per year, and Fox making a higher bid for the rights, in a likely effort to establish itself as a "live sports and news" network in the wake of selling a majority of assets to Disney (DIS). On the digital side, Facebook (FB) declined to make an offer for digital streaming rights to TNF, while Amazon (AMZN), which paid $50M this year, and Twitter (TWTR), which paid $10M last year did submit bids.
01/18/18
01/18/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Symantec (SYMC) downgraded to Underperform from Hold at Jefferies with analyst John DiFucci saying the company's current guidance is not achievable and the stock will rerate lower upon investor realization. 2. Juno Therapeutics (JUNO) downgraded to Neutral from Buy at Citi with analyst Robyn Karnauskas saying Juno could be worth $110 per share in a takeover. 3. Comcast (CMCSA) downgraded to Neutral from Buy at Nomura Instinet with analyst Jeffrey Kvaal saying the company faces "heightened challenges" with over-the-top services driving declines in linear video and broadband growth likely to slow. 4. First Solar (FSLR) downgraded to Neutral from Buy at Guggenheim with analyst Sophie Karp citing valuation and limited near-term catalysts. 5. Chevron (CVX) downgraded to Hold from Buy at HSBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/18/18
MOFT
01/18/18
NO CHANGE
Target $52
MOFT
Buy
Comcast price target raised to $52 from $45 at MoffettNathanson
MoffettNathanson analyst Craig Moffett raised Comcast's price target to $52 from $45 citing tax reform benefits.
01/25/18
RHCO
01/25/18
NO CHANGE
Target $50
RHCO
Buy
Comcast price target raised to $50 from $45 at SunTrust
SunTrust analyst Greg Miller raised his price target on Comcast to $50 and kept his Buy rating after "solid" Q4 earnings, citing a more aggressive cash repatriation and encouraging guidance. Miller notes that while cable results were slightly below estimates, NBCU saw more "top-line momentum" and Xfinity wireless continued to gain subscribers. The analyst says he is bullish on the company's ability to grow and "generate significant free cash".
SKYAY Sky
$61.60

-0.18 (-0.29%)

04/26/17
JEFF
04/26/17
UPGRADE
JEFF
Buy
Sky upgraded to Buy from Hold at Jefferies
Price target GBP 1,200p.
08/01/17
FBCO
08/01/17
NO CHANGE
Target $37
FBCO
Outperform
21st Century Fox, Sky deal to take longer to clear, says Credit Suisse
Credit Suisse analyst Omar Sheikh continues to believe the Sky (SKYAY) transaction will eventually receive full regulatory approval, but highlights there is an elevated risk to the deal if it is referred to the CMA, and at best an extended period before it gets cleared. Meanwhile, he believes the 2018 21st Century Fox (FOXA) organic equity story looks compelling, and reiterates an Outperform rating and $37 price target on the shares.
10/12/17
FBCO
10/12/17
NO CHANGE
Target $35
FBCO
Outperform
21st Century Fox price target lowered to $35 from $37 at Credit Suisse
Credit Suisse analyst Omar Sheikh lowered his price target for 21st Century Fox (FOXA) to $35 from $37 ahead of Q1 earnings. The analyst notes that the key near-term headwinds are soft NFL ratings and the risk that the Sky (SKYAY) transaction is blocked by U.K. regulators. The analyst reiterates an Outperform rating on 21st Century Fox shares.
04/04/17
PIVT
04/04/17
NO CHANGE
Target $36
PIVT
Buy
Boycotts of O'Reilly Factor likely manageable for now, says Pivotal Research
Pivotal Research analyst Brian Wieser said advertiser boycotts of O'Reilly Factor are likely manageable and only slightly negative at this time, but added that a more significant concern is the potential for this to impact Ofcom's "fit and proper" test related to Fox's (FOXA) proposed takeover of Sky (SKYAY). Wieser, who views the Sky acquisition as a favorable strategic combination, would sees the U.K. regulator not allowing the transaction to proceed as a negative. However, he keeps a Buy rating and $36 price target on Fox shares.
M Macy's
$27.45

(0.00%)

02/05/18
JEFF
02/05/18
NO CHANGE
Target $100
JEFF
Buy
Bon-Ton Stores bankruptcy benefits Kohl's, says Jefferies
Jefferies analyst Randal Konik notes that Bon-Ton Stores filed bankruptcy protection and provided the locations of the about 50 units slated for closure. The analyst now estimates near-term closures from Macy's (M), Sears (SHLD), Kmart, and Bon-Ton (BONT) should add about 18c to Kohl's (KSS) EPS and a 1.5% comp lift. Moreover, Konik believes the materialization of Bon-Ton's closures could be a "cherry on top" to accelerating fundamentals at Kohl's this year. He reiterates a Buy rating and $100 price target on Kohl's shares.
12/18/17
OTRG
12/18/17
UPGRADE
OTRG
Mixed
Macy's upgraded to Mixed from Negative at OTR Global
OTR Global upgraded Macy's to Mixed following checks that indicate sell-through is meeting or exceeding plan driven by strong ecommerce trends.
01/02/18
MSCO
01/02/18
NO CHANGE
MSCO
Kohl's, Macy's Q4 same-store sales estimates raised at Morgan Stanley
Morgan Stanley analyst Kimberly Greenberger said that overall retail traffic appeared solid following Christmas, adding that store checks and third party data points suggest better performance at Kohl's (KSS) and Macy's (M) than she originally anticipated. Greenberger raised her Q4 Kohl's comparable sales estimate to down 1% from down 3% and increased her comp sales estimate for Macy's to down 2% from down 2.5%. However, she maintains an Underweight rating on Kohl's shares and an Equal Weight rating on Macy's.
01/05/18
BMOC
01/05/18
NO CHANGE
Target $38
BMOC
Outperform
Macy's price target raised to $38 from $35 at BMO Capital
BMO Capital analyst Wayne Hood raised his price target on Macy's to $38 and kept his Outperform rating after the company's Nov-Dec comps completed the first positive SSS Q4 since 2014. Hood notes "encouraging" improvement in brick-and-mortar comps as well as double digit growth in digital platforms, forecasting further upside from " improving consumer spending setup from tax reform and falling unemployment that could be far reaching". The analyst raises his FY17 EPS forecast to $3.63 from $3.53 and FY18 forecast to $3.18 from $2.63, reflecting a lower effective tax rate of about 25%.
MNK Mallinckrodt
$16.19

(0.00%)

01/08/18
WELS
01/08/18
NO CHANGE
WELS
Market Perform
Mallinckrodt news likely to viewed as slight negative, says Wells Fargo
Wells Fargo analyst David Maris believes Mallinckrodt's sale today of two hemostasis products will likely be viewed as slightly negative since it is dilutive and reverses a prior deal. At the time of the original acquisition, Mallinckrodt said it was strategically expanding its hospital presence and cited the innovative profiles, high growth potential, and durability of Recothrom and Preveleak, Maris tells investors in a research note. He keeps a Market Perform on the shares.
01/05/18
UBSW
01/05/18
DOWNGRADE
Target $18
UBSW
Neutral
Sucampo downgraded to Neutral from Buy at UBS
UBS analyst Marc Goodman downgraded Sucampo Pharmaceuticals (SCMP) to Neutral to reflect the takeover by Mallinckrodt (MNK). The analyst believes the deal is likely to close without significant issues and upped his price target for the shares to $18 from $15.
02/02/18
LEHM
02/02/18
DOWNGRADE
Target $20
LEHM
Underweight
Mallinckrodt downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao downgraded Mallinckrodt to Underweight and cut his price target for the shares to $20 from $23. The acquisition of Sucampo (SCMP) does not address ongoing concern over Acthar and reduces the company's strategic options by raising leverage to 4.5 times, Tsao tells investors in a research note. Reimbursement pressure for Acthar could intensify, and, while not imminent, the franchise could face competition, the analyst adds.
01/09/18
BMOC
01/09/18
NO CHANGE
BMOC
Outperform
BMO Capital 'pleased' with Mallinckrodt steps to evolve portfolio
After Mallinckrodt (MNK) announced the divestiture of hemostasis products Recothrom and Preveleak to Baxter (BAX) for $185M, BMO Capital analyst Gary Nachman said he was "pleased" with these moves and the company's recent deal for Sucampo (SCMP) as steps toward evolving its portfolio and reducing Acthar concentration risk. While saying there is still more to do, Nachman believes Mallinckrodt's expanding pipeline warrants more attention and he keeps an Outperform rating on the stock.
THC Tenet
$19.07

(0.00%)

01/03/18
GSCO
01/03/18
INITIATION
Target $15
GSCO
Neutral
Tenet initiated with a Neutral at Goldman Sachs
Goldman analyst Stephen Tanal initiated Tenet with a Neutral and $15 price target due to unattractive payor mix, difficult local positioning, and competitive threats.
12/20/17
MSCO
12/20/17
DOWNGRADE
MSCO
Underweight
HCA Healthcare, Tenet downgraded to Underweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Zack Sopcak downgraded HCA Healthcare (HCA) and Tenet (THC), both to Underweight from Equal Weight, contending that the recently announced deals made by Aetna (AET) for CVS Health (CVS) and UnitedHealthcare (UNH) for DaVita Medical Group highlight the ways payers are becoming increasingly vertically integrated and focusing on reducing medical costs. After analyzing CVS Health's overlap with hospitals and hospitals' exposure to CVS and UnitedHealth (UNH) clinics in states with above average Medicare Advantage share, Sopcak found HCA and Tenet to be most exposed, he tells investors. Noting that he sees the valuations of both as full, he raised his price target on HCA to $84 from $79 and increased his target on Tenet to $15 from $14.
12/20/17
MSCO
12/20/17
DOWNGRADE
MSCO
Underweight
Tenet downgraded to Underweight from Equal Weight at Morgan Stanley
12/20/17
LEER
12/20/17
NO CHANGE
Target $27
LEER
Outperform
Value may be unlocked through Tenet sale of Conifer, says Leerink
Leerink analyst Ana Gupte raised her price target for Tenet to $27 from $25 on increased confidence that value may be unlocked through the active sale of Conifer. The analyst believes Conifer sales proceeds could be used for further debt reduction or growth opportunities in the ambulatory segment. He reiterates an Outperform rating on the shares.
PANW Palo Alto Networks
$169.32

(0.00%)

02/27/18
STFL
02/27/18
NO CHANGE
Target $200
STFL
Buy
Palo Alto Networks price target raised to $200 from $180 at Stifel
Stifel analyst Gur Talpaz said Palo Alto Networks' Q2 results topped consensus expectations "across all major financial metrics," noting that the company's ancillary solutions are becoming a tangible driver of incremental walletshare gains. He maintains a Buy rating on Palo Alto and increased his price target on the stock to $200 following the "clean beat and raise" report.
02/27/18
RBCM
02/27/18
NO CHANGE
Target $200
RBCM
Outperform
Palo Alto Networks price target raised to $200 from $185 at RBC Capital
RBC Capital analyst Matthew Hedberg raised his price target on Palo Alto Networks to $200 after Q2 earnings beat, saying the company enjoys the benefit of its "largest-ever product refresh" while its applications extend its value proposition to consolidate security spending. The analyst points to the management's assessment of growth drivers through improved salesforce execution, competitive strengths of the platform, and new product introduction and cross-selling. Hedberg keeps his Outperform rating on Palo Alto Networks, noting it is "one of the premier next-generation security companies, well positioned to benefit from an increasingly complex security and threat landscape".
02/27/18
BARD
02/27/18
NO CHANGE
Target $190
BARD
Neutral
Baird would look for Palo Alto pullbacks to get more constructive
Baird analyst Jayson Noland noted Palo Alto Networks posted another solid quarter and continues to drive traction in Cloud and Endpoint. The analyst said he remains positive on the shares, but would wait for a pullback to get more constructive. Noland maintained his Neutral rating, though he raised his price target to $190 from $160 on Palo Alto shares.
02/27/18
MAXM
02/27/18
NO CHANGE
Target $212
MAXM
Buy
Palo Alto Networks price target raised to $212 from $196 at Maxim
Maxim analyst Nehal Chokshi raised his price target on Palo Alto Networks to $212 after the company's Q2 results, stating that the management's bullish 2017 analyst day projections are poised to begin playing out in Q3 as sales productivity start to improve. Chokshi believes that the implied Q4 outlook also appears to be conservative given that the product refresh is driving the upside. The analyst keeps his Buy rating on Palo Alto Networks, adding that the power of the company's platform is also apparent from the ongoing subscription revenue increases.
AKRX Akorn
$30.28

0.16 (0.53%)

02/26/18
RAJA
02/26/18
NO CHANGE
RAJA
Market Perform
Akorn takeover by Fresenius 'may be kaput,' says Raymond James
In a research note titled "Die Fusion ist Kaput? Data Integrity Issues Likely Torpedo Fresenius Buy of AKRX," Raymond James analyst Elliot Wilbur believes the data integrity issues at Akorn (AKRX) could not only impact the company's approved products, but also its pipeline. Fresenius (FSNUY) has consistently touted the pipeline as key to the acquisition, which is now likely to be compromised, Wilbur contends. He believes Akorn could be valued at $8 per share if data integrity issues exist and the company's existing portfolio or pipeline are compromised. Akorn's base generics business has seen a "dramatic deterioration" over the past three quarters, Wilbur points out. He keeps a Market Perform rating on the stock.
02/27/18
JEFF
02/27/18
NO CHANGE
Target $34
JEFF
Hold
Akorn takeover by Fresenius may be in doubt, says Jefferies
The alleged Akorn (AKRX) data breaches by Fresenius SE (FSNUY) may put the terms of the merger agreement in doubt, Jefferies analyst David Steinberg tells investors in a research note. The use of consultants seems to signal Fresenius is looking to reprice or possibly terminate the merger, the analyst contends. He notes, however, that merger experts have generally viewed the transaction as "ironclad." Steinberg keeps a Hold rating on Akorn with a $34 price target.
10/16/17
WELS
10/16/17
NO CHANGE
WELS
Outperform
Court ruling looks 'clearly negative' for Allergan, says Wells Fargo
Wells Fargo analyst David Maris says a federal judge ruling today that Allergan's (AGN) Restasis patents are invalid "appears clearly negative" for the company. Due to the magnitude of the potential damages involved, however, an at-risk generic launch is unlikely, Maris tells investors in an intraday research note. As such, the analyst continues to believe the earliest that a generic version of Restasis may enter the market is sometime in 2019. Maris keeps an Outperform rating on Allergan. He adds that today's court ruling is incrementally positive for generic Restasis filers, if approved, including Teva (TEVA), Mylan ( MYL) and Akorn (AKRN).
02/22/18
DBAB
02/22/18
NO CHANGE
DBAB
Hold
Akorn may be worth $9-$17 if Fresenius deal breaks, says Deutsche Bank
A "simple analysis implies significant downside" in shares of Akorn (AKRX) if the Fresenius SE (FSNUY) takeover breaks, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. The analyst notes that since a speech on February 2 by the acting director of the Bureau of Competition at the FTC Bruce Hoffman, where he suggested that in transactions where complex drugs need to be divested, the FTC will require the divestiture of on-market products rather than pipeline products, the deal spread on Akorn's stock price and the $34 per share cash offer price has averaged 7% and is currently close to 8%. Assuming EBITDA multiples of 9-13 times for a standalone Akorn, the stock has a theoretical value of $9-$15 based on the company's Q3 EBITDA annualized and an $11-$17 share price based on estimated 2018 EBITDA, Gilbert writes. He keeps a Hold rating on Akorn with a $34 price target. He believes that the widening spread suggests concerns about the deal.
FSNUY Fresenius SE
$20.14

0.475 (2.42%)

11/17/17
UBSW
11/17/17
DOWNGRADE
UBSW
Sell
Fresenius SE downgraded to Sell from Neutral at UBS
UBS analyst Ian Douglas-Pennant downgraded Fresenius SE to Sell saying he expects pricing pressure to spread to injectables. The rate of injectable generic drug approvals in the U.S. has increased 40% over the past year years, and those to compete against Fresenius' Kabi more than tripled, the analyst contends. He cut his price target for the shares to EUR 57 from EUR 74.
NTRI Nutrisystem
$39.90

-1.65 (-3.97%)

02/06/18
CHLM
02/06/18
NO CHANGE
Target $80
CHLM
Buy
Craig-Hallum remains a buyer of Nutrisystem as Google trends continue to lag
Craig-Hallum analyst Alex Fuhrman says Nutrisystem (NTRI) Google (GOOG; GOOGL) trends continue to lag, setting up a buying opportunity despite mixed indicators. Mixed indicators suggest the Nutrisystem brand is not likely to accelerate revenue growth in 2018 from 2017's 23% levels, however the analyst believes there is still strong potential to exceed his estimate of about 11% growth for the brand in 2018. He reiterates a Buy rating and $80 price target on Nutrisystem's shares.
02/27/18
RILY
02/27/18
NO CHANGE
Target $52
RILY
Buy
Nutrisystem price target lowered to $52 from $74 at B. Riley FBR
B. Riley FBR analyst Kara Anderson lowered her price target for Nutrisystem to $52 saying marketing missteps in early 2018 drove fiscal year guidance well below consensus. The analyst reduced her estimates but maintains a Buy rating on the shares.
02/27/18
BRRR
02/27/18
DOWNGRADE
BRRR
Market Perform
Nutrisystem downgraded to Market Perform from Outperform at Barrington
Barrington analyst Matthew Gall downgraded Nutrisystem to Market Perform following last night's Q4 results. The company's flattish guidance for 2018, compared to double-digit growth expectations on sales and earnings, will likely put a ceiling on the stock for the next couple of quarters, Galls tells investors in a research note. 2018 may well prove to be a reset year for Nutrisystem, the analyst adds. The stock in pre-market trading is down 27%, or $10.80, to $29.10.
02/27/18
CHLM
02/27/18
NO CHANGE
Target $50
CHLM
Buy
Nutrisystem price target lowered to $50 from $80 at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman lowered his price target for Nutrisystem to $50 from $80, citing guidance below estimates as the company "uncharacteristically" overpaid for pre-bought ads on Fox News (FOXA) & CNN (TWX). The analyst reiterates a Buy rating on Nutrisystem's shares.
VERI Veritone
$18.09

2.71 (17.62%)

02/20/18
ROTH
02/20/18
NO CHANGE
Target $32
ROTH
Buy
Veritone price target lowered to $32 from $62 at Roth Capital
Roth Capital analyst Darren Aftahi lowered his price target for Veritone to $32 from $62 as he is taking a more conservative approach going into FY18. Nonetheless, the analyst reiterates a Buy rating on the shares as he anticipates an above-consensus Q4 when the company reports quarterly results. Aftahi expects further insight on Veritone's potential for acquisitions in FY18, which he believes is one of the strongest catalysts for continued growth going forward.
02/27/18
RILY
02/27/18
NO CHANGE
Target $10
RILY
Sell
Veritone price target lowered to $10 from $15 at B. Riley FBR
B. Riley FBR analyst Sameet Sinha lowered his price target for Veritone to $10 following the company's Q4 results and keeps a Sell rating on the shares.
02/27/18
CHLM
02/27/18
NO CHANGE
Target $23
CHLM
Buy
Veritone price target lowered to $23 from $31 at Craig-Hallum
Craig-Hallum analyst Chad Bennett lowered his price target for Veritone to $23 from $31 after the company reported Q4 results below his estimates as both the media agency business and AI Platform revenue came in lower than he anticipated. The analyst reiterates a Buy rating on the shares.
02/27/18
ROTH
02/27/18
NO CHANGE
Target $27
ROTH
Buy
Veritone price target lowered to $27 from $32 at Roth Capital
Roth Capital analyst Darren Aftahi lowered his price target for Veritone to $27 from $32 after the company reported Q4 results below expectations, although it made notable progress across key metrics. The analyst reiterates a Buy rating on the shares.
FIT Fitbit
$5.54

(0.00%)

02/27/18
OPCO
02/27/18
NO CHANGE
Target $8
OPCO
Outperform
Fitbit transition starts 'modestly,' says Oppenheimer
Oppenheimer analyst Andrew Uerkwitz says Fitbit reported another "uninteresting" quarter. But with reactivations, cash being essentially flat, and recent digital health acquisitions, the analyst remains "ever the optimist." Uerkwitz reiterates an Outperform rating and $8 price target.
02/27/18
BOFA
02/27/18
NO CHANGE
Target $5
BOFA
Underperform
Fitbit price target lowered to $5,outlook disappoints, says BofA/Merrill
BofA/Merrill analyst Ryan Goodman said Fitbit's Q4 report and outlook fell short of expectations with its new flagship smartwatch, Iconic, experiencing weak sales as it faced competitive challenges. Goodman said the underwhelming reception of Iconic is a "worrisome sign" due to the importance of the launch and raises concerns as to Fitbit's ability to take market share. The analyst lowered his 2018 Fitbit revenue estimate to $1.5B from $1.78B and cut his price target to $5 from $6 given declining revenue, cash burn and product uncertainty, while maintaining and Underperform rating.
02/27/18
SBSH
02/27/18
NO CHANGE
Target $4.5
SBSH
Sell
Fitbit price target lowered to $4.50 from $5 at Citi
Citi analyst Stanley Kovler lowered his price target for Fitbit to $4.50 citing the company's Q4 miss and guide down. The analyst maintains a Sell rating on the shares.
02/27/18
STFL
02/27/18
NO CHANGE
Target $5.5
STFL
Hold
Stifel keeps Hold on Fitbit, says expense management reassuring
Stifel analyst Jim Duffy said Fitbit's Q4 results and FY18 outlook were "directionally aligned" with his expectations, though he added that he is reassured by the company's expense management and inventory discipline. Duffy maintains a Hold rating and $5.50 price target on Fitbit, stating that he doesn't yet see a path to profitability and is "challenged to make a compelling upside case" for the stock.
EXEL Exelixis
$29.53

0.02 (0.07%)

02/27/18
OPCO
02/27/18
UPGRADE
Target $40
OPCO
Outperform
Exelixis upgraded to Outperform with $40 target at Oppenheimer
Oppenheimer analyst Leah Rush Cann upgraded Exelixis to Outperform from Perform with a $40 price target. The analyst is now applying a valuation methodology for profitable companies to Exelixis, since the company turned profitable for the full-year 2017. She expects Exelixis will continue to develop its commercial drugs, Cabometyx and Cometriq, while its partner Genentech will continue to develop Cotellic. Cann views the company's Q4 results as "strong."
01/04/18
PIPR
01/04/18
NO CHANGE
Target $37
PIPR
Overweight
Piper ups Exelixis target to $37, names a top pick for 2018
Piper Jaffray analyst Edward Tenthoff names Exelixis a top pick for 2018 and raised his price target for the shares to $37 from $33. The analyst expects Cabometyx growth from driven label expansion and is positive into the Phase III Cotexo data in the first half of 2018.
02/27/18
OPCO
02/27/18
UPGRADE
OPCO
Outperform
Exelixis upgraded to Outperform from Perform at Oppenheimer
10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.

TODAY'S FREE FLY STORIES

TWTR

Twitter

$44.49

-0.775 (-1.71%)

12:44
07/15/18
07/15
12:44
07/15/18
12:44
Periodicals
Twitter suspends accounts linked to Russians indicted by Mueller, Reuters says »

Twitter has suspended two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 27

    Jul

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:29
07/15/18
07/15
12:29
07/15/18
12:29
Periodicals
Trump says he will run for reelection, Reuters reports »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

12:22
07/15/18
07/15
12:22
07/15/18
12:22
Periodicals
Airbus in talks for repeat Viva Aerobus jet order, Reuters says »

Airbus is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$350.81

4.79 (1.38%)

12:19
07/15/18
07/15
12:19
07/15/18
12:19
Periodicals
Boeing concerned about tariff talk, Reuters reports »

Boeing is concerned about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:17
07/15/18
07/15
12:17
07/15/18
12:17
Periodicals
President Trump calls EU a 'foe' on trade, Reuters reports »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$279.57

0.3 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$203.32

1.29 (0.64%)

12:14
07/15/18
07/15
12:14
07/15/18
12:14
Hot Stocks
L3 Technologies appoints new SVP, Chief Global Business Development Officer »

L3 Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$207.33

0.43 (0.21%)

, TWTR

Twitter

$44.49

-0.775 (-1.71%)

13:27
07/14/18
07/14
13:27
07/14/18
13:27
Periodicals
Facebook, Alphabet to testify at U.S. House hearing, Reuters reports »

The U.S. House Judiciary…

FB

Facebook

$207.33

0.43 (0.21%)

TWTR

Twitter

$44.49

-0.775 (-1.71%)

GOOG

Alphabet

$1,188.81

4.94 (0.42%)

GOOGL

Alphabet Class A

$1,204.34

2.43 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 27

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

AAPL

Apple

$191.32

0.19 (0.10%)

, T

AT&T

$31.66

-0.56 (-1.74%)

13:06
07/14/18
07/14
13:06
07/14/18
13:06
Periodicals
Apple's next iPhone may be debut of eSIM, Barron's says »

Apple's (AAPL) next…

AAPL

Apple

$191.32

0.19 (0.10%)

T

AT&T

$31.66

-0.56 (-1.74%)

VZ

Verizon

$51.41

0.17 (0.33%)

S

Sprint

$5.66

(0.00%)

TMUS

T-Mobile

$61.68

0.09 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 09

    Aug

AEP

American Electric

$70.37

-0.02 (-0.03%)

, NEE

NextEra Energy

$169.60

1.06 (0.63%)

12:57
07/14/18
07/14
12:57
07/14/18
12:57
Periodicals
Utility stocks worth a second look, Barron's says »

Utility stocks like…

AEP

American Electric

$70.37

-0.02 (-0.03%)

NEE

NextEra Energy

$169.60

1.06 (0.63%)

XEL

Xcel Energy

$46.26

-0.09 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

AVGO

Broadcom

$202.46

-7.45 (-3.55%)

, CA

CA Technologies

$44.07

-0.08 (-0.18%)

12:50
07/14/18
07/14
12:50
07/14/18
12:50
Periodicals
Broadcom testing investors' faith, Barron's says »

For a while, shareholders…

AVGO

Broadcom

$202.46

-7.45 (-3.55%)

CA

CA Technologies

$44.07

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$23.40

-0.84 (-3.47%)

, HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

12:16
07/14/18
07/14
12:16
07/14/18
12:16
Periodicals
Ackman might be making a comeback, Barron's says »

Bill Ackman's…

VRX

Valeant

$23.40

-0.84 (-3.47%)

HLF

Herbalife Nutrition

$53.95

-0.14 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 27

    Aug

ARNC

Arconic

$17.39

0.08 (0.46%)

, APO

Apollo Global

$36.13

0.26 (0.72%)

08:41
07/14/18
07/14
08:41
07/14/18
08:41
Periodicals
Apollo, other PE firms express interest in Arconic, WSJ reports »

Arconic (ARNC) has…

ARNC

Arconic

$17.39

0.08 (0.46%)

APO

Apollo Global

$36.13

0.26 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

PFE

Pfizer

$37.53

0.01 (0.03%)

, BABA

Alibaba

$190.03

-0.14 (-0.07%)

08:23
07/14/18
07/14
08:23
07/14/18
08:23
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

PFE

Pfizer

$37.53

0.01 (0.03%)

BABA

Alibaba

$190.03

-0.14 (-0.07%)

BIDU

Baidu

$267.20

-4.31 (-1.59%)

JD

JD.com

$38.27

-0.25 (-0.65%)

IQ

iQIYI

$33.92

-1.12 (-3.20%)

VIPS

Vipshop

$10.23

-0.09 (-0.87%)

NYT

New York Times

$25.60

-0.6 (-2.29%)

PLNT

Planet Fitness

$48.71

1.2 (2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

  • 10

    Sep

XYL

Xylem

$68.55

0.485 (0.71%)

, AQUA

Evoqua Water

$20.71

(0.00%)

04:55
07/14/18
07/14
04:55
07/14/18
04:55
Conference/Events
RBC Capital to hold a field trip »

Asia Water Sector Field…

XYL

Xylem

$68.55

0.485 (0.71%)

AQUA

Evoqua Water

$20.71

(0.00%)

DHR

Danaher

$99.25

-0.4 (-0.40%)

PNR

Pentair

$43.53

0.67 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 25

    Jul

  • 07

    Aug

HJLI

Hancock Jaffe Laboratories

$3.20

-0.025 (-0.78%)

18:20
07/13/18
07/13
18:20
07/13/18
18:20
Hot Stocks
Hancock Jaffe Laboratories names Bob Rankin as CFO, effective July 16 »

Hancock Jaffe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CKH

Seacor

$53.63

0.69 (1.30%)

, LPG

Dorian LPG

$7.92

0.115 (1.47%)

18:16
07/13/18
07/13
18:16
07/13/18
18:16
Hot Stocks
Seacor favors combination of Dorian LPG and BW LPG Limited »

Seacor (CKH) announced…

CKH

Seacor

$53.63

0.69 (1.30%)

LPG

Dorian LPG

$7.92

0.115 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:53
07/13/18
07/13
17:53
07/13/18
17:53
Hot Stocks
Senator Rubio says ZTE 'should be put out of business' »

U.S. Senator Marco Rubio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

TEVA

Teva

$23.29

-0.45 (-1.90%)

, NVS

Novartis

$78.78

-0.15 (-0.19%)

17:47
07/13/18
07/13
17:47
07/13/18
17:47
Hot Stocks
FDA announces voluntary recall of several medicines containing valsartan »

The U.S. Food and Drug…

TEVA

Teva

$23.29

-0.45 (-1.90%)

NVS

Novartis

$78.78

-0.15 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 16

    Sep

SKY

Skyline

$32.54

-0.13 (-0.40%)

17:26
07/13/18
07/13
17:26
07/13/18
17:26
Syndicate
Breaking Syndicate news story on Skyline »

Skyline files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$32.54

-0.13 (-0.40%)

17:25
07/13/18
07/13
17:25
07/13/18
17:25
Syndicate
Breaking Syndicate news story on Skyline »

Skyline files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBIO

Mustang Bio

$7.49

0.09 (1.22%)

17:24
07/13/18
07/13
17:24
07/13/18
17:24
Syndicate
Breaking Syndicate news story on Mustang Bio »

Mustang Bio files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$76.26

0.42 (0.55%)

, XLU

Utilities SPDR

$52.56

0.04 (0.08%)

17:15
07/13/18
07/13
17:15
07/13/18
17:15
General news
Week ending ETF Scorecard: Industrials rebound into lead, Utilities lag »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$76.26

0.42 (0.55%)

XLU

Utilities SPDR

$52.56

0.04 (0.08%)

IYR

DJ US Real Estate Index Fund

$81.37

-0.19 (-0.23%)

XLP

Consumer Staples Sector SPDR

$52.73

0.32 (0.61%)

XLY

Consumer Discretionary Sector SPDR

$112.62

0.27 (0.24%)

XLB

S&P Select Materials SPDR

$58.59

-0.02 (-0.03%)

XLF

Financial Select Sector

$26.96

-0.13 (-0.48%)

XLV

Health Care Select Sector SPDR

$87.44

0.18 (0.21%)

XLK

Technology Select Sector SPDR

$72.56

-0.07 (-0.10%)

XLI

Industrial Select Sector SPDR

$73.77

0.43 (0.59%)

GLD

SPDR Gold Trust

$117.60

-0.515 (-0.44%)

SLV

iShares Silver Trust

$14.88

-0.13 (-0.87%)

USO

United States Oil Fund

$14.47

0.085 (0.59%)

UNG

United States Natural Gas Fund

$22.40

-0.3 (-1.32%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.63

0.005 (0.01%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.76

0.16 (0.14%)

TLT

iShares 20+ Year Treasury Bond Fund

$122.74

0.33 (0.27%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.60

0.165 (0.16%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

0.025 (0.03%)

IWD

iShares Russell 1000 Value

$123.04

-0.07 (-0.06%)

IWF

iShares Russell 1000 Growth

$149.33

0.33 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$1.04

-0.015 (-1.42%)

17:15
07/13/18
07/13
17:15
07/13/18
17:15
Hot Stocks
CEL-SCI receives noncompliance letter from NYSE »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$53.47

-0.18 (-0.34%)

17:13
07/13/18
07/13
17:13
07/13/18
17:13
Hot Stocks
Yankees suspend relationship with Papa John's »

The New York Yankees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

NCNA

NuCana

$24.00

-0.01 (-0.04%)

17:08
07/13/18
07/13
17:08
07/13/18
17:08
Hot Stocks
Breaking Hot Stocks news story on NuCana »

Christopher B. Wood…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.